Veincentre currently operates nine clinics across the UK including Bristol, London, Manchester, Nottingham, Newcastle Under Lyme, Oxfordshire, Southampton and Stoke on Trent.
Since the investment, Veincentre has launched two new clinics in Glasgow and Leeds and is set to open a new clinic in Birmingham in the Spring.
This new funding from Santander will facilitate the expansion of additional clinics as it looks to launch a Liverpool site next month and a further two new clinics before the end of the year.
Veincentre is also investing in digital transformation with the development of a new website and digital marketing strategy.
David West, medical director at Veincentre, said: ‘Our ambition is to provide an affordable service to as many patients as possible, and a key part of this is making sure we have a presence in each of the UK’s major cities and regions.
‘Palatine’s investment, along with the support from the team, is helping us realise that vision, and this additional funding will facilitate further expansion.’
Established in 2003, Veincentre is a specialist medical centre for the diagnosis and treatment of varicose veins. It uses Endovenous Laser Ablation (EVLA), a non-invasive, non-surgical treatment for varicose veins which benefits from reduced surgical and recovery times, as well as reduced signs of scarring and damage.
Veincentre is the UK’s only medical practice specialising in just treating varicose veins following the withdrawal of NHS funding for varicose vein sufferers in 2018.